共找到 20 条结果
Deep learning methods have permeated into the research area of computer-aided drug design. The deep learning generative model and classical algorithm can be simultaneously used for three-dimensional (3D) drug design in the 3D pocket of the receptor. Here, three aspects of MolAICal are illustrated for drug design: in the first part, the MolAICal uses the genetic algorithm, Vinardo score and deep learning generative model trained by generative adversarial net (GAN) for drug design. In the second part, the deep learning generative model is trained by drug-like molecules from the drug database such as ZINC database. The MolAICal invokes the deep learning generative model and molecular docking for drug virtual screening automatically. In the third part, the useful drug tools are added for calculating the relative properties such as Pan-assay interference compounds (PAINS), Lipinski's rule of five, synthetic accessibility (SA), and so on. Besides, the structural similarity search and quantitative structure-activity relationship (QSAR), etc are also embedded for the calculations of drug properties in the MolAICal. MolAICal will constantly optimize and develop the current and new modules f
Drug research and development are embracing translational research for its potential to increase the number of drugs successfully brought to clinical applications. Using the publicly available PubMed database, we sought to describe the status of drug translational research, the distribution of translational lags for all drugs as well as the collaborations between basic science and clinical science in drug research. For each drug, an indicator called Translational Lag was proposed to quantify the interval time from its first PubMed article to its first clinical article. Meanwhile, the triangle of biomedicine was also used to visualize the status and multidisciplinary collaboration of drug translational research. The results showed that only 18.1% (24,410) of drugs/compounds had been successfully entering clinical research. It averagely took 14.38 years (interquartile range, 4 to 21 years) for a drug from the initial basic discovery to its first clinical research. In addition, the results also revealed that, in drug research, there was rare cooperation between basic science and clinical science, which were more inclined to cooperate within disciplines.
The birth of ChatGPT, a cutting-edge language model-based chatbot developed by OpenAI, ushered in a new era in AI. However, due to potential pitfalls, its role in rigorous scientific research is not clear yet. This paper vividly showcases its innovative application within the field of drug discovery. Focused specifically on developing anti-cocaine addiction drugs, the study employs GPT-4 as a virtual guide, offering strategic and methodological insights to researchers working on generative models for drug candidates. The primary objective is to generate optimal drug-like molecules with desired properties. By leveraging the capabilities of ChatGPT, the study introduces a novel approach to the drug discovery process. This symbiotic partnership between AI and researchers transforms how drug development is approached. Chatbots become facilitators, steering researchers towards innovative methodologies and productive paths for creating effective drug candidates. This research sheds light on the collaborative synergy between human expertise and AI assistance, wherein ChatGPT's cognitive abilities enhance the design and development of potential pharmaceutical solutions. This paper not only
In the context of clinical research, computational models have received increasing attention over the past decades. In this systematic review, we aimed to provide an overview of the role of so-called in silico clinical trials (ISCTs) in medical applications. Exemplary for the broad field of clinical medicine, we focused on in silico (IS) methods applied in drug development, sometimes also referred to as model informed drug development (MIDD). We searched PubMed and ClinicalTrials.gov for published articles and registered clinical trials related to ISCTs. We identified 202 articles and 48 trials, and of these, 76 articles and 19 trials were directly linked to drug development. We extracted information from all 202 articles and 48 clinical trials and conducted a more detailed review of the methods used in the 76 articles that are connected to drug development. Regarding application, most articles and trials focused on cancer and imaging-related research while rare and pediatric diseases were only addressed in 14 articles and 5 trials, respectively. While some models were informed combining mechanistic knowledge with clinical or preclinical (in-vivo or in-vitro) data, the majority of
This report summarizes the research outcomes achieved by the research group at Hokkaido University under the funding program "Innovative Information and Communications Technology Research and Development (Commissioned Research)" of the National Institute of Information and Communications Technology (NICT). Although this report is primarily written for specialists in the fields of optics and computational science, the content has been concisely organized to ensure accessibility and interest for a broader readership.
Early identification of sensitive cancer cell lines is essential for accelerating biomarker discovery and elucidating drug mechanism of action. Given the efficiency and low cost of small-scale drug screens relative to extensive omics profiling, we compared drug-response panel (DRP) descriptors against omics features for predictive capacity using gradient boosting tree models across the GDSC and CCLE drug response datasets. DRP descriptors consistently outperformed omics data across key performance metrics, with variable performance across different drugs. Using complementary explainability approaches, we confirmed known MAPK-inhibitor sensitivity signatures, and identified novel potential biomarker candidates for MEK1/2 and BTK/MNK inhibitors. Lastly, to demonstrate the utility of this approach in distinguishing phenotypes, we applied our models to the breast cancer line MCF7 versus the non-tumorigenic MCF10A, and successfully identified compounds that selectively inhibit MCF7 while sparing the non-tumorigenic MCF10A. This methodology, developed using focused drug and cell line panels, supports early-stage drug development by facilitating rational cell line selection and compound p
The integration of Large Language Models (LLMs) into the drug discovery and development field marks a significant paradigm shift, offering novel methodologies for understanding disease mechanisms, facilitating drug discovery, and optimizing clinical trial processes. This review highlights the expanding role of LLMs in revolutionizing various stages of the drug development pipeline. We investigate how these advanced computational models can uncover target-disease linkage, interpret complex biomedical data, enhance drug molecule design, predict drug efficacy and safety profiles, and facilitate clinical trial processes. Our paper aims to provide a comprehensive overview for researchers and practitioners in computational biology, pharmacology, and AI4Science by offering insights into the potential transformative impact of LLMs on drug discovery and development.
Applying Design Science Research (DSR) methodology is becoming a popular working resource for most Information Systems (IS) and Software engineering studies. The research and/or practical design problems that must be faced aim to answer the question of how to create or investigate an artifact in a given context. Precisely characterizing both artifact and context is essential for effective research development. While various design science guidelines and frameworks have been created by experts in IS engineering, emerging researchers and postgraduate students still find it challenging to apply this research methodology correctly. There is limited literature and materials that guide and support teaching novice researchers about the types of artifacts that can be developed to address a particular problem and decision-making in DSR. To address this gap in DSR, in this chapter, we explore DSR from an educational perspective, explaining both the concept of DSR and an effective method for teaching it. This chapter includes examples of DSR, a teaching methodology, learning objectives, and recommendations. Moreover, we have created a survey artifact intended to gather data on the experiences
Developing drugs for rare diseases presents unique challenges from a statistical perspective. These challenges may include slowly progressive diseases with unmet medical needs, poorly understood natural history, small population size, diversified phenotypes and geneotypes within a disorder, and lack of appropriate surrogate endpoints to measure clinical benefits. The Real-World Evidence (RWE) Scientific Working Group of the American Statistical Association Biopharmaceutical Section has assembled a research team to assess the landscape including challenges and possible strategies to address these challenges and the role of real-world data (RWD) and RWE in rare disease drug development. This paper first reviews the current regulations by regulatory agencies worldwide and then discusses in more details the challenges from a statistical perspective in the design, conduct, and analysis of rare disease clinical trials. After outlining an overall development pathway for rare disease drugs, corresponding strategies to address the aforementioned challenges are presented. Other considerations are also discussed for generating relevant evidence for regulatory decision-making on drugs for rare
The goal of this research is to uncover the channels through which research and development (R&D) impacts economic growth in developing countries. The study employed nine variables from three broader categories in the World Economic Forum database, each covering 32 countries from the lower-middle-income group for the year 2019. The theoretical framework is based on the R&D ecosystem, which includes components such as Institutions, Human capital, Capital market, R&D, and Innovation. Each of these components can contribute to the economic development of the country. Using Structural Equation Modelling (SEM), we build a path diagram to visualize and confirm a potential relationship between the components. R&D features had a positive impact on innovation (regression weight estimate: +0.34, p = 0.001), as did capital market institutions (regression weight estimate: +0.12, p = 0.007), but neither had a significant impact on growth. According to the Schumpeterian institutional interpretation, R&D and innovation efforts may not lead to sustained growth in middle-income countries. We find no significant connection between innovation performance and economic growth. This
Clinical trials are an indispensable part of the drug development process, bridging the gap between basic research and clinical application. During the development of new drugs, clinical trials are used not only to evaluate the safety and efficacy of the drug but also to explore its dosage, treatment regimens, and potential side effects. This review discusses the various stages of clinical trials, including Phase I (safety assessment), Phase II (preliminary efficacy evaluation), Phase III (large-scale validation), and Phase IV (post-marketing surveillance), highlighting the characteristics of each phase and their interrelationships. Additionally, the paper addresses the major challenges encountered in clinical trials, such as ethical issues, subject recruitment difficulties, diversity and representativeness concerns, and proposes strategies for overcoming these challenges. With the advancement of technology, innovative technologies such as artificial intelligence, big data, and digitalization are gradually transforming clinical trial design and implementation, improving trial efficiency and data quality. The article also looks forward to the future of clinical trials, particularly
In this paper, we review recent developments and the role of Graph Neural Networks (GNNs) in computational drug discovery, including molecule generation, molecular property prediction, and drug-drug interaction prediction. By summarizing the most recent developments in this area, we underscore the capabilities of GNNs to comprehend intricate molecular patterns, while exploring both their current and prospective applications. We initiate our discussion by examining various molecular representations, followed by detailed discussions and categorization of existing GNN models based on their input types and downstream application tasks. We also collect a list of commonly used benchmark datasets for a variety of applications. We conclude the paper with brief discussions and summarize common trends in this important research area.
Despite the significant advances in life science, it still takes decades to translate a basic drug discovery into a cure for human disease. To accelerate the process from bench to bedside, interdisciplinary research (especially research involving both basic research and clinical research) has been strongly recommend by many previous studies. However, the patterns and the roles of the interdisciplinary characteristics in drug research have not been deeply examined in extant studies. The purpose of this study was to characterize interdisciplinary characteristics in drug research from the perspective of translational science, and to examine the role of different kinds of interdisciplinary characteristics in translational research for drugs.
The role of Artificial Intelligence (AI) is growing in every stage of drug development. Nevertheless, a major challenge in drug discovery AI remains: Drug pharmacokinetic (PK) and Drug-Target Interaction (DTI) datasets collected in different studies often exhibit limited overlap, creating data overlap sparsity. Thus, data curation becomes difficult, negatively impacting downstream research investigations in high-throughput screening, polypharmacy, and drug combination. We propose xImagand-DKI, a novel SMILES/Protein-to-Pharmacokinetic/DTI (SP2PKDTI) diffusion model capable of generating an array of PK and DTI target properties conditioned on SMILES and protein inputs that exhibit data overlap sparsity. We infuse additional molecular and genomic domain knowledge from the Gene Ontology (GO) and molecular fingerprints to further improve our model performance. We show that xImagand-DKI-generated synthetic PK data closely resemble real data univariate and bivariate distributions, and can adequately fill in gaps among PK and DTI datasets. As such, xImagand-DKI is a promising solution for data overlap sparsity and may improve performance for downstream drug discovery research tasks. Code
Drug resistance is a serious public health problem that threatens to thwart our ability to treat many infectious diseases. Repeatedly, the introduction of new drugs has been followed by the evolution of resistance. In principle there are two ways to address this problem: (i) enhancing drug development, and (ii) slowing drug resistance. We present data and a modeling approach based on queueing theory that explores how interventions aimed at these two facets affect the ability of the entire drug supply system to provide service. Analytical and simulation-based results show that, all else equal, slowing the evolution of drug resistance is more effective at ensuring an adequate supply of effective drugs than is enhancing the rate at which new drugs are developed. This lends support to the idea that evolution management is not only a significant component of the solution to the problem of drug resistance, but may in fact be the most important component.
In the era of targeted therapy, there has been increasing concern about the development of oncology drugs based on the "more is better" paradigm, developed decades ago for chemotherapy. Recently, the US Food and Drug Administration (FDA) initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development. To accommodate this paradigm shifting, we propose a dose-ranging approach to optimizing dose (DROID) for oncology trials with targeted drugs. DROID leverages the well-established dose-ranging study framework, which has been routinely used to develop non-oncology drugs for decades, and bridges it with established oncology dose-finding designs to optimize the dose of oncology drugs. DROID consists of two seamlessly connected stages. In the first stage, patients are sequentially enrolled and adaptively assigned to investigational doses to establish the therapeutic dose range (TDR), defined as the range of doses with acceptable toxicity and efficacy profiles, and the recommended phase 2 dose set (RP2S). In the second stage, patients are randomized to the doses in RP2S to assess the dose-response relationship and identify the optimal dose.
This paper presents a scientometric analysis of research output from the University of Lagos, focusing on the two decades spanning 2004 to 2023. Using bibliometric data retrieved from the Web of Science, we examine trends in publication volume, collaboration patterns, citation impact, and the most prolific authors, departments, and research domains at the university. The study reveals a consistent increase in research productivity, with the highest publication output recorded in 2023. Health Sciences, Engineering, and Social Sciences are identified as dominant fields, reflecting the university's interdisciplinary research strengths. Collaborative efforts, both locally and internationally, show a positive correlation with higher citation impact, with the United States and the United Kingdom being the leading international collaborators. Notably, open-access publications account for a significant portion of the university's research output, enhancing visibility and citation rates. The findings offer valuable insights into the university's research performance over the past two decades, providing a foundation for strategic planning and policy formulation to foster research excellence
The US Food and Drug Administration (FDA) has been actively promoting the use of real-world data (RWD) in drug development. RWD can generate important real-world evidence reflecting the real-world clinical environment where the treatments are used. Meanwhile, artificial intelligence (AI), especially machine- and deep-learning (ML/DL) methods, have been increasingly used across many stages of the drug development process. Advancements in AI have also provided new strategies to analyze large, multidimensional RWD. Thus, we conducted a rapid review of articles from the past 20 years, to provide an overview of the drug development studies that use both AI and RWD. We found that the most popular applications were adverse event detection, trial recruitment, and drug repurposing. Here, we also discuss current research gaps and future opportunities.
Demographic data collection is essential in education research, as demographic data allows researchers to better describe the participant population they study and to contextualize findings. However, current research practices for neurodiversity demographics often rely on prescriptive methods (e.g., requiring participants to report official diagnoses) rather than allowing participants to self-identify. This approach can: a) not allow participants to express their intersecting identities in ways that are authentic; and b) limit trustworthiness and reliability of the data and interpretation. In addition, inconsistent dissemination and representation of demographic data across studies hinder the accessibility and usability of this work. Through a literature review of neurodivergent student experiences with learning and performing STEM, we identified widespread discrepancies in how demographic information is collected and reported. This paper explores how neurodivergent identities can be more accurately and inclusively represented in education research. We present findings of a thematic analysis on the ways neurodivergent demographic data collection is done in the literature using data
Gamification is a technological, economic, cultural, and societal development toward promoting a more game-like reality. As this emergent phenomenon has been gradually consolidated into our daily lives, especially in educational settings, many scholars and practitioners face a major challenge ahead: how to understand and mitigate the unethical impacts of gamification when researching and developing such educational technologies? Thus, this study explores ethical challenges in gamified educational applications and proposes potential solutions to address them based on an umbrella review. After analysing secondary studies, this study details and proposes recommendations on addressing some ethical challenges in gamified education, such as power dynamics and paternalism, lack of voluntarity and confidentiality, cognitive manipulation, and social comparison. Research and development decision-making processes affected by such challenges are also elaborated, and potential actions to mitigate their effects in gamification planning, conducting and communication are further introduced. Thus, this chapter provides an understanding of ethical challenges posed by the literature in gamified educa